Clinical trial
Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's…
NCT00104819 · Favrille, Industry · Terminated
Key facts
| NCT number | NCT00104819 |
|---|---|
| Title | Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma |
| Official title | Phase II Trial of FavId™ (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive FavId on Study FavId-06 |
| Lead sponsor | Favrille, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim |
| Enrollment | 238 |
| Start date | Sep 1, 2004 |
| Primary completion | Jun 1, 2011 |
| First posted | Mar 4, 2005 |
| Last update posted | Aug 2, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: